Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.50 |
| ▸ | GRM5 | P41594 | 11/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2100256 | 0.87 | NAMPT (0.36) | PDK4GRM1GRM5NAMPTCDK9 | |
| SCHEMBL18739607 | 0.86 | PDK4 (0.54) | PDK4GRM1GRM5NAMPTHTR6 | |
| SCHEMBL30270466 | 0.85 | PDK4 (0.63) | PDK4GRM1GRM5NAMPTHTR6 | |
| SCHEMBL4542408 | 0.81 | GRM1 (0.56) | PDK4GRM1GRM5NAMPTHTR6 | |
| SCHEMBL3545758 | 0.81 | PDK4 (0.58) | PDK4GRM1GRM5NAMPTHTR6 | |
| SCHEMBL3466789 | 0.81 | PDK4 (0.58) | PDK4GRM1GRM5NAMPTHTR6 | |
| SCHEMBL2877448 | 0.80 | PDK4 (0.57) | PDK4GRM1GRM5NAMPTHTR6 | |
| SCHEMBL29915662 | 0.79 | PDK4 (0.56) | PDK4GRM1GRM5NAMPTHTR6 | |
| SCHEMBL17223048 | 0.79 | PDK4 (0.56) | PDK4GRM1GRM5NAMPTHTR6 | |
| SCHEMBL12883597 | 0.77 | PDK4 (0.53) | PDK4GRM1GRM5NAMPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163737-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163737-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163737-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| WO-2009020470-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020470-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, GRPR | PDK4 4302/4885GRM1 419/4885GRM5 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.